Valuation: Outlook Therapeutics, Inc.

Market Cap 141M 122M 115M 104M 196M 13.53B 200M 1.35B 526M 6.77B 531M 520M 22.51B P/E 2026 *
-1.3x
P/E 2027 * -3.2x
Enterprise Value 141M 122M 115M 104M 196M 13.53B 200M 1.35B 526M 6.77B 531M 520M 22.51B EV / Sales 2026 *
-1,414x
EV / Sales 2027 * 2.52x
Free-Float
85.03%
Yield 2026 *
-
Yield 2027 * -
1 day-14.90%
1 week-25.84%
Current month-22.55%
1 month-48.19%
3 months+231.61%
6 months+54.37%
Current year-52.13%
1 week 0.71
Extreme 0.712
1.18
1 month 0.71
Extreme 0.712
1.75
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
3.39
3 years 0.16
Extreme 0.1611
29.2
5 years 0.16
Extreme 0.1611
57.3
10 years 0.16
Extreme 0.1611
878.4
Manager TitleAgeSince
Chief Executive Officer 54 2025-06-30
Chief Executive Officer 60 2024-12-02
Chief Tech/Sci/R&D Officer - 2023-01-18
Director TitleAgeSince
Director/Board Member 60 2018-08-01
Director/Board Member 65 2015-12-10
Chairman 41 2025-01-30
Date Insider Type Main position Quantity % Market Cap.
7/29/26 Buy

Chairman

95,398 0.0642%
7/21/26 Free

Chief Executive Officer

100,000 0.0673%
7/21/26 Free

Chief Financial Officer

210,078 0.1414%
Change 5-day change 1-year change 3-year change Capi.($)
-14.90%-25.84%-67.68%-97.22% 141M
+0.07%-2.80%+1.37%+19.06% 48.42B
+0.85%-0.70%+460.88%+581.30% 43.66B
-2.40%-0.23%+8.13%+80.67% 39.51B
-2.01%-0.85%+23.85%+9.97% 38.95B
-0.50%+0.85%+20.60%+58.18% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+126.36% 16.15B
-1.45%-0.86%+3.12%+26.72% 14.16B
-0.43%+4.70%+78.74%+38.66% 13.37B
Average -2.10%-2.90%+61.71%+93.74% 26.33B
Weighted average by Cap. -0.68%-0.64%+95.66%+140.50%

Financials

2026 *2027 *
Net sales -100K -86.37K -81.16K -73.81K -139K -9.56M -141K -951K -372K -4.79M -375K -367K -15.91M 56.05M 48.41M 45.49M 41.37M 77.78M 5.36B 79.06M 533M 208M 2.68B 210M 206M 8.92B
Net income -62.6M -54.07M -50.81M -46.21M -86.87M -5.99B -88.3M -595M -233M -3B -235M -230M -9.96B -36.77M -31.76M -29.84M -27.14M -51.02M -3.52B -51.86M -350M -137M -1.76B -138M -135M -5.85B
Net Debt - -
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
26-08-14 $0.7564 -14.90% 104,623,239
26-08-13 $0.8888 -19.20% 82,392,948
26-08-12 $1.100 -2.65% 8,070,070
26-08-11 $1.130 -1.74% 6,090,376
26-08-10 $1.150 +12.75% 10,314,162
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.7564USD
Average target price
5.400USD
Spread / Average Target
+613.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock